Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Duffaud

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
The Lancet. Oncology|April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trialOlivier Mir, Claire Cropet, Maud Toulmonde, et al.
Bulletin Du Cancer|March 29, 2023
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group]Coriolan Lebreton, Pierre Meeus, Catherine Genestie, et al.
The Lancet. Oncology|November 28, 2018
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 studyFlorence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, et al.
BMC Cancer|February 8, 2013
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use programJean-Yves Blay, Antoine Italiano, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life settingStéphane Bouchet, Sylvie Poulette, Karine Titier, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2022
Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCTGeert Spierenburg, Peter Grimison, Christine Chevreau, et al.
The Lancet. Oncology|March 25, 2018
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trialHans Gelderblom, Claire Cropet, Christine Chevreau, et al.
International Journal of Cancer|September 25, 2021
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma GroupElise Lavit, Mihaela Aldea, Sophie Piperno-Neumann, et al.
Plos One|September 19, 2018
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinibOlivier Bouché, Axel Le Cesne, Maria Rios, et al.
The Lancet. Oncology|July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trialOlivier Mir, Claire Cropet, Maud Toulmonde, et al.
Bulletin Du Cancer|March 29, 2023
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group]Coriolan Lebreton, Pierre Meeus, Catherine Genestie, et al.
The Lancet. Oncology|November 28, 2018
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 studyFlorence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, et al.
BMC Cancer|February 8, 2013
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use programJean-Yves Blay, Antoine Italiano, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life settingStéphane Bouchet, Sylvie Poulette, Karine Titier, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2022
Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCTGeert Spierenburg, Peter Grimison, Christine Chevreau, et al.
The Lancet. Oncology|March 25, 2018
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trialHans Gelderblom, Claire Cropet, Christine Chevreau, et al.
International Journal of Cancer|September 25, 2021
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma GroupElise Lavit, Mihaela Aldea, Sophie Piperno-Neumann, et al.
Plos One|September 19, 2018
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinibOlivier Bouché, Axel Le Cesne, Maria Rios, et al.
The Lancet. Oncology|July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Pageof 14